A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

February 20, 2026

Study Completion Date

December 26, 2027

Conditions
Breast CancerOvarian CancerEndometrial Cancer
Interventions
DRUG

BL0175

"BL0175 is a nano-medicine for cancer therapy. Nano-medicine means the tiny size of this study drug allows it to enter and concentrate into the tumor tissue. This is a new way of delivering an active drug (an estrogen receptor down regulator) for the treatment of tumor directly into tumor tissue."

Trial Locations (2)

130000

RECRUITING

The First Hospital of Jilin University, Changchun

250000

RECRUITING

Jinan Central Hospital, Jinan

All Listed Sponsors
lead

Shanghai Best-Link Bioscience, LLC

INDUSTRY